Natco Pharma Ltd

The approved product is bioequivalent to Halaven Injection, the reference-listed drug (RLD) marketed by Eisai Inc. Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for metastatic disease. It is also used for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. According to IQVIA MAT data for April 2026, the reference drug Halaven recorded estimated annual sales of approximately $43.7 million in the United States. NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore posted in the corresponding quarter last year. Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. The counter slipped 2.48% to Rs 915.80 on the BSE. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25 and higher by 24.42% from Rs 1,180.50 crore in Q3 FY26. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. It increased 4.1% sequentially from Rs 7100.5 crore in Q3 FY26. The counter shed 0.20% to Rs 2,245.10 on the BSE. Powered by Capital Market - Live

Net profit of Natco Pharma declined 34.11% to Rs 267.90 crore in the quarter ended March 2026 as against Rs 406.60 crore during the previous quarter ended March 2025. Sales declined 39.47% to Rs 739.10 crore in the quarter ended March 2026 as against Rs 1221.00 crore during the previous quarter ended March 2025. For the full year,net profit declined 24.76% to Rs 1418.50 crore in the year ended March 2026 as against Rs 1885.40 crore during the previous year ended March 2025. Sales declined 7.93% to Rs 4078.30 crore in the year ended March 2026 as against Rs 4429.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales739.101221.00 -39 4078.304429.50 -8 OPM %17.2644.89 -35.2249.58 - PBDT194.50604.20 -68 1697.402526.60 -33 PBT144.10505.90 -72 1490.802291.40 -35 NP267.90406.60 -34 1418.501885.40 -25 Powered by Capital Market - Live

Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25. On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26. For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Powered by Capital Market - Live

Delta Corp Ltd, ISGEC Heavy Engineering Ltd, Jyoti CNC Automation Ltd and Bharat Dynamics Ltd are among the other losers in the BSE's 'A' group today, 29 May 2026.Natco Pharma Ltd tumbled 10.70% to Rs 1049.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.18 lakh shares were traded on the counter so far as against the average daily volumes of 53556 shares in the past one month.Delta Corp Ltd lost 8.62% to Rs 74.01. The stock was the second biggest loser in 'A' group.On the BSE, 26.91 lakh shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month.ISGEC Heavy Engineering Ltd crashed 8.55% to Rs 944.4. The stock was the third biggest loser in 'A' group.On the BSE, 10635 shares were traded on the counter so far as against the average daily volumes of 3711 shares in the past one month.Jyoti CNC Automation Ltd dropped 8.06% to Rs 604. The stock was the fourth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 70030 shares in the past one month.Bharat Dynamics Ltd fell 7.90% to Rs 1182. The stock was the fifth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 89799 shares in the past one month.Powered by Capital Market - Live

Natco Pharma will hold a meeting of the Board of Directors of the Company on 29 May 2026.

The company had received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study. The drug is used for the treatment of adults suffering from inadequately controlled Type 2 diabetes, along with diet and exercise. NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANAT and SEMAFULL. Multi dose vials will be launched at MRP of Rs 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of Rs 1,750 for 8mg/3ml. Pen device will be priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April'26. The company said that it is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator's brand. NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company's consolidated net profit jumped 13.9% to Rs 151.50 crore on a 36.3% increase in revenue from operations to Rs 647.30 crore in Q3 FY26 over Q3 FY25.Powered by Capital Market - Live

NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry. NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study.  Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi dose vials will be launched at MRP of INR 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of INR 1,750 for 8mg/3ml. Pen device will be priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April'26. NATCO is the first company to offer generic Semaglutide in multi dose vials with customised syringes. NATCO is also offering the product to third parties for co-marketing. Powered by Capital Market - Live

Natco Pharma will hold a meeting of the Board of Directors of the Company on 24 March 2026.Powered by Capital Market - Live

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg, and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics. NATCO said based on information made available by the U.S. Food and Drug Administration (FDA), it believes that it has 180 days of shared exclusivity. Pomalidomide Capsules 1 mg, 2 mg, 3 mg, and 4 mg had estimated sales of $3.2 billion in the U.S. for the 12 months ending September 2025, the company said, citing industry sales data. Rajeev Nannapaneni, vice chairman and chief executive officer of NATCO Pharma, said, 'We are pleased to launch Pomalidomide Capsules in the U.S.; this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.' NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company's consolidated net profit jumped 13.9% to Rs 151.50 crore on a 36.3% increase in revenue from operations to Rs 647.30 crore in Q3 FY26 over Q3 FY25.Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals Ltd, RHI Magnesita India Ltd, Brainbees Solutions Ltd, Inox Wind Ltd are among the other stocks to see a surge in volumes on NSE today, 16 February 2026.Natco Pharma Ltd witnessed volume of 188.67 lakh shares by 14:14 IST on NSE, a 30.19 times surge over two-week average daily volume of 6.25 lakh shares. The stock increased 9.68% to Rs.903.60. Volumes stood at 4.52 lakh shares in the last session.Akums Drugs & Pharmaceuticals Ltd registered volume of 22.18 lakh shares by 14:14 IST on NSE, a 21.84 fold spurt over two-week average daily volume of 1.02 lakh shares. The stock rose 6.35% to Rs.480.00. Volumes stood at 70716 shares in the last session.RHI Magnesita India Ltd registered volume of 13.51 lakh shares by 14:14 IST on NSE, a 9.47 fold spurt over two-week average daily volume of 1.43 lakh shares. The stock rose 4.88% to Rs.457.95. Volumes stood at 1.13 lakh shares in the last session.Brainbees Solutions Ltd clocked volume of 77.54 lakh shares by 14:14 IST on NSE, a 7.68 times surge over two-week average daily volume of 10.10 lakh shares. The stock lost 10.49% to Rs.241.50. Volumes stood at 10.2 lakh shares in the last session.Inox Wind Ltd notched up volume of 456.78 lakh shares by 14:14 IST on NSE, a 6.18 fold spurt over two-week average daily volume of 73.91 lakh shares. The stock slipped 3.03% to Rs.103.16. Volumes stood at 78.58 lakh shares in the last session.Powered by Capital Market - Live